Search form
Search
contact us
Navigation
home
boards
Jobs
job ratings
cp wire
medtech news
pharmagather
catering
advertise
whistleblower info
pharmaceutical fraud
medical device | DME fraud
clinical lab fraud
False Claims Act
Legal Help
login/register
You are here
Home
»
companies
» Sandoz
Sandoz
Novartis, staring down tough market for M&A, leans toward $25B Sandoz spinoff: Bloomberg
Fierce Pharma
Fri, 07/1/22 - 09:49 am
Novartis
spinoffs
generics
M&A
Sandoz
private equity
More drug, fewer jabs: Novartis' Sandoz eyes EMA nod for high-concentration Humira copy
Fierce Pharma
Mon, 06/20/22 - 10:37 am
Novartis
Sandoz
AbbVie
Humira
Europe
biosimilars
autoimmune disease
EMA
Hyrimoz
Novartis’ Sandoz Launches Biosimilars Awareness Campaign to Improve Biosimilars Adoption Worldwide
Xtalks
Wed, 06/8/22 - 11:04 pm
Novartis
Sandoz
biosimilars
generics
Novartis' Sandoz founds new initiative to expand biosimilar use more globally
Endpoints
Tue, 05/31/22 - 11:51 pm
Novartis
Sandoz
biosimilars
Novartis' Sandoz strikes at Roche with first US generic of blockbuster Esbriet
Fierce Pharma
Fri, 05/13/22 - 10:46 am
Novartis
Sandoz
generics
Roche
Esbriet
idiopathic pulmonary fibrosis
Novartis' Sandoz, following Pfizer's lead, launches 2nd carcinogen-related drug recall this week
Fierce Pharma
Wed, 03/23/22 - 10:58 pm
Novartis
Sandoz
product recalls
generics
Novo Nordisk and Novartis put Victoza patent suit to bed, teeing up Sandoz copycat by 2024
Fierce Pharma
Wed, 03/23/22 - 10:38 am
Novo Nordisk
Novartis
Sandoz
Victoza
generics
patents
diabetes
Sandoz bulks up ahead of possible sale with Coalesce buy
Pharmaforum
Mon, 03/14/22 - 10:21 am
Novartis
Sandoz
generics
M&A
Coalesce Product Development
Novartis sells pair of manufacturing plants as Sandoz strategic review rolls on
Fierce Pharma
Thu, 03/3/22 - 10:19 am
Novartis
drug manufacturing
Sandoz
No news anytime soon on Sandoz sale, says Novartis
Pharmaforum
Thu, 02/3/22 - 10:35 am
Novartis
Vas Narasimhan
Sandoz
generics
M&A
Novartis (NVS) Q4 Earnings & Sales Miss, Sandoz Review Ongoing
NASDAQ
Wed, 02/2/22 - 11:44 pm
Novartis
earnings
Sandoz
Novartis' Sandoz reportedly the target of $25B buyout bid from Carlyle and Blackstone
Fierce Pharma
Tue, 02/1/22 - 11:26 pm
Novartis
Sandoz
M&A
Blackstone
Carlyle
Teva and Novartis’ Sandoz launch Narcan generics on same day, brand marketer Emergent remains in play
Endpoints
Wed, 01/5/22 - 10:47 pm
Teva Pharmaceutical
Novartis
Sandoz
generics
Narcan
Emergent BioSolutions
Spinoff updates: Merck’s Organon and Novartis’ Sandoz
Generics and Biosimilar Initiative
Mon, 11/29/21 - 11:08 pm
spinoffs
Merck
Organon
earnings
Novartis
Sandoz
biosimilars
EQT, Biontech investor family consider Sandoz bid
Yahoo/Reuters
Fri, 11/19/21 - 11:12 am
EQT
BioNTech
Sandoz
generics
Novartis
M&A
Swiss socialists say government should buy Sandoz
Pharmaforum
Mon, 11/8/21 - 10:38 am
Switzerland
Novartis
Sandoz
M&A
generics
What Novartis could buy with its windfall
EP Vantage
Fri, 11/5/21 - 09:40 am
Novartis
M&A
Roche
Sandoz
Aurinia Pharmaceuticals
Alnylam
Exelixis
Incyte
Eisai
Genmab
Novartis looking into future of its Sandoz’ generics business
Pharmaforum
Tue, 10/26/21 - 10:30 am
Novartis
generics
Sandoz
Three generic firms shell out $447M more to settle federal price fixing allegations
Endpoints
Mon, 10/4/21 - 10:59 am
generics
legal
price fixing
Taro Pharmaceuticals
Sandoz
Novartis
Apotex
Amgen scores Otezla patent win, protecting its blockbuster from Sandoz and Zydus generics until 2028
Fierce Pharma
Tue, 09/21/21 - 10:54 am
Amgen
Otezla
psoriasis
generics
Sandoz
market exclusivity
patents
Pages
« first
‹ previous
1
2
3
4
5
6
7
8
9
…
next ›
last »